Recent Updates
Recently added Catalysts

AT-752

Phase 1

Dengue | Small molecule | Infectious Disease |Atea Pharmaceuticals, Inc.|Last Updated: Oct 17, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment65

FDA Designations

No designations recorded

Clinical trial landscape

AT-752 · 1 trial · 1 indication

Phase 1 1
NCT04722627Study of AT-752 in Healthy SubjectsDengue
COMPLETED65 Analytics
PHASE1COMPLETED
Study of AT-752 in Healthy Subjects
Dengue
NCT0472262765
Unlock trial analytics

Study Endpoints

Primary Endpoints

Proportions (active vs. Placebo) of subjects experiencing treatment-emergent adverse events
Day 6 for single dose or Day 12 for multiple dose
Pharmacokinetics (PK) of AT-752 of single and multiple ascending oral doses
Day 1 for subjects receiving a single fasted dose; Days 1 and 7 for subjects receiving multiple doses

Maximum plasma concentration (Cmax)

Effect of food on Pharmacokinetics (PK) of AT-752 of a single oral dose
Day 1 for subjects receiving a single fed dose]

Maximum plasma concentration (Cmax)

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
AT-752 250 mg single doseEXPERIMENTALAT-752 administered orally, 250 mg on Day 1
Placebo -single dosePLACEBO_COMPARATORMatching placebo administered orally on Day 1
AT-752 500 mg single doseEXPERIMENTALAT-752 administered orally, 500 mg single doses on Day 1 and Day 7
Placebo- single dosePLACEBO_COMPARATORMatching placebo administered orally on Day 1 and Day 7
AT-752 1000 mg single doseEXPERIMENTALAT-752 administered orally, 1000 mg single dose on Day 1
Placebo - single dosePLACEBO_COMPARATORMatching placebo administered orally on Day 1
AT-752 1500 mg single doseEXPERIMENTALAT-752 administered orally, 1500 mg single dose on Day 1
Placebo: single dosePLACEBO_COMPARATORMatching placebo administered orally on Day 1
AT-752 - 1000 mg QD multiple dosesEXPERIMENTALAT-752 - administered orally, 1000 mg once daily (QD) for 7 days
Placebo - Administered once daily (QD)PLACEBO_COMPARATORMatching placebo administered orally once daily (QD) for 7 days
AT-752 - 750 mg twice daily (BID)EXPERIMENTALAT-752 administered orally, 750 mg twice daily (BID) for 4 days plus one dose on Day 5.
Placebo - Administered twice daily (BID)PLACEBO_COMPARATORMatching placebo administered orally twice daily (BID) for 4 days plus one dose on Day 5.
AT-752 - 750 mg three times daily (TID)EXPERIMENTALAT-752 administered orally, 750 mg three times daily (TID) for 4 days plus one dose on Day 5.
Placebo - Administered TIDPLACEBO_COMPARATORMatching placebo administered orally (TID) for 4 days plus one dose on Day 5.

Interventions

NameTypeDescription
AT-752DRUGParallel Assignment
PlaceboDRUGParallel Assignment
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Body mass index (BMI) of 18-29 kg/m2 2. Must agree to use protocol-specified methods of contraception 3. Negative pregnancy test 4. Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: 1. Pregnant or breastfeeding 2. Abus...

Countries:Australia
Unlock Eligibility Criteria

Competitive Landscape -Dengue 10 trials

CompanyTickerTrialsLead PhaseDrugs
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE3Tetravalent Dengue Vaccine
Novartis AG Sponsored ADRNVS1PHASE2EYU688
Sanofi SA Sponsored ADRSNY1 - Undisclosed
Abbott LaboratoriesABT1 - Undisclosed
Danaher CorporationDHR1 - Undisclosed
Unlock Competitive Intelligence

Frequently asked questions about AT-752

What is AT-752 used for?

AT-752 is an investigational small molecule being developed for the treatment of dengue, a viral infection transmitted by mosquitoes. It is currently in Phase 1 clinical development, meaning it has not yet been approved for any use and is still being studied for safety and tolerability in humans.

What does AT-752 target?

AT-752 is a small molecule antiviral designed to target dengue virus. While the specific molecular target is not disclosed, it is being studied for its potential to treat dengue infection. The drug is in Phase 1 clinical trials to evaluate its safety and pharmacokinetics in healthy volunteers.

Who is developing AT-752?

AT-752 is being developed by Atea Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious diseases. The company is listed on the stock exchange under the ticker symbol AVIR. Atea is conducting clinical trials to evaluate the safety and tolerability of AT-752 in healthy subjects.

What phase is AT-752 in?

AT-752 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities for any use. The Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers.

What clinical trials is AT-752 in?

AT-752 has one completed Phase 1 clinical trial, identified by the National Clinical Trial number NCT04722627. This trial, titled 'Study of AT-752 in Healthy Subjects,' enrolled 65 participants in Australia. The study was a randomized, double-blind, placebo-controlled trial involving healthy volunteers aged 18 years and older.

Is AT-752 the same as any other drug?

AT-752 is a distinct investigational drug candidate developed by Atea Pharmaceuticals. No alternative names have been reported for this compound. It is being studied specifically for the treatment of dengue and is not known to be identical to any other approved or investigational medication.